# Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)

> **NCT00693056** · PHASE2 · COMPLETED · sponsor: **Rexahn Pharmaceuticals, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Erectile Dysfunction (ED)

## Interventions

- **DRUG:** Placebo
- **DRUG:** RX-10100 5mg
- **DRUG:** RX-10100 10mg
- **DRUG:** RX-10100 15mg

## Key facts

- **NCT ID:** NCT00693056
- **Lead sponsor:** Rexahn Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-03
- **Final completion:** 2009-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2009-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00693056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00693056, "Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00693056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*